SCHEMBL1717153

SCHEMBL1717153

CCOC(=O)CC1CCN(Cc2c(C(=O)NC(CC)c3ccccc3)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 11/20 0.43
TACR2 P21452 6/20 0.43
OPRM1 P35372 5/20 0.43
LMNA P02545 1/20 0.42
KCNK3 O14649 3/20 0.42
MCHR1 Q99705 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TRPV4 Q9HBA0 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
TACR1 P25103 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1717030 0.89 KMT2A (0.51) TACR3TACR2OPRM1MEN1KMT2A
SCHEMBL1718723 0.88 TACR3 (0.46) TACR3TACR2OPRM1LMNAMCHR1
SCHEMBL1718399 0.88 TACR3 (0.43) TACR3TACR2OPRM1MEN1KMT2A
SCHEMBL1718029 0.87 TACR3 (0.47) TACR3TACR2OPRM1LMNAMCHR1
SCHEMBL1717716 0.87 TACR3 (0.47) TACR3TACR2OPRM1LMNAMCHR1
SCHEMBL1716895 0.86 TACR3 (0.45) TACR3TACR2OPRM1MEN1KMT2A
SCHEMBL1717594 0.86 TACR3 (0.46) TACR3TACR2OPRM1KCNK3MCHR1
SCHEMBL1717416 0.86 TACR3 (0.47) TACR3TACR2OPRM1LMNAMCHR1
SCHEMBL1719397 0.85 TACR3 (0.45) TACR3TACR2OPRM1MCHR1TRPV4
SCHEMBL1718981 0.85 TACR3 (0.48) TACR3TACR2OPRM1KCNK3MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TACR3 30/4885TACR2 31/4885OPRM1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.